Browse KIF20A

Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus Cytoplasm, cytoskeleton, spindle
Domain PF00225 Kinesin motor domain
Function

Mitotic kinesin required for chromosome passenger complex (CPC)-mediated cytokinesis. Following phosphorylation by PLK1, involved in recruitment of PLK1 to the central spindle. Interacts with guanosine triphosphate (GTP)-bound forms of RAB6A and RAB6B. May act as a motor required for the retrograde RAB6 regulated transport of Golgi membranes and associated vesicles along microtubules. Has a microtubule plus end-directed motility.

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0000281 mitotic cytokinesis
GO:0000910 cytokinesis
GO:0000920 cell separation after cytokinesis
GO:0001578 microtubule bundle formation
GO:0007018 microtubule-based movement
GO:0061640 cytoskeleton-dependent cytokinesis
Molecular Function GO:0003774 motor activity
GO:0003777 microtubule motor activity
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0016887 ATPase activity
Cellular Component GO:0005819 spindle
GO:0005871 kinesin complex
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0030496 midbody
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-983189: Kinesins
R-HSA-68886: M Phase
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-68884: Mitotic Telophase/Cytokinesis
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KIF20A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between KIF20A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23714729Malignant Head and Neck NeoplasmPromote immunity (T cell function); essential for immunotherapyWe identified promiscuous KIF20A-LPs bearing naturally processed epitopes recognized by CD4(+) T cells and CTLs. KIF20A-specific CTLs were induced by vaccination with a KIF20A-LP in vivo. KIF20A expression was detected in 55% of HNMT by immunohistochemistry, and significant frequencies of KIF20A-specific TH1 cell responses were detected after short-term in vitro stimulation of PBMCs with KIF20A-LPs in 50% of HNMT patients, but not in healthy donors. Furthermore, these responses were associated with KIF20A expression in HNMT tissues.
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KIF20A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KIF20A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6080.0572
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7290.566
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5280.625
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1720.671
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1430.924
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5720.765
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0730.853
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5690.674
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6080.649
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1290.878
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.360.763
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4350.00154
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KIF20A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIF20A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIF20A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIF20A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIF20A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KIF20A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KIF20A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKIF20A
Namekinesin family member 20A
Aliases RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KIF20A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.